OTC · Medical - Pharmaceuticals

Nippon Shinyaku Co., Ltd. (NPPNY) Stock

$6.00 +0.00% OTC: NPPNY Healthcare

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally.

Valuation

MetricValue
Price$6.00
Market Cap$1.62B
P/E Ratio9.11
P/B Ratio0.93
P/S Ratio1.59
EPS (TTM)$0.66
52-Week High$15.21
52-Week Low$5.03
Dividend Yield1.83%

Financials & Margins

MetricValue
ROE10.94%
ROA8.58%
ROCE10.86%
Gross Margin66.35%
Operating Margin19.34%
Net Margin17.40%
Debt/Equity0.01
Current Ratio4.35

Annual Financials (USD)

Metric20222023202420252026
Revenue$137.5B$144.2B$148.3B$160.2B$181.1B
Operating Profit$32.9B$30.0B$31.4B$36.8B$35.0B
Net Profit$25.0B$22.8B$25.9B$32.6B$31.5B
EPS$92.74$84.68$95.96$120.82$116.64
Op Margin24.0%20.8%21.2%22.9%19.3%

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$219.9B$237.5B$263.4B$283.6B$347.9B
Total Liabilities$39.1B$41.5B$42.9B$36.3B$54.7B
Cash$60.6B$60.0B$58.1B$55.2B$76.9B
Borrowings$2.7B$2.7B$2.9B$2.7B$2.6B

Latest News

Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy PR Newswire · Jun 26, 2026 Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy GlobeNewswire · Jun 26, 2026 NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children's Hospital PR Newswire · Jun 23, 2026 All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6% Stocktwits · Jun 17, 2026 Regenxbio Shares Rise After Positive Duchenne Trial Results InvestorsHub · May 14, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$21.3B$26.2B$16.3B$36.1B$28.9B
Investing Cash Flow$-19.0B$-29.4B$-19.6B$-26.4B$-1.1B
Financing Cash Flow$-1.6B$-1.8B$-1.7B$-1.6B$-1.7B
Net Cash Flow$2.7B$-519.0M$-2.0B$-2.9B$28.8B
Free Cash Flow$12.4B$14.4B$6.6B$32.8B$25.7B

Valuation & Return Ratios

MetricValue
PEG Ratio-1.04
EV / EBITDA4.55
FCF Yield8.95%
Quick Ratio3.12
Interest Coverage198.99
Return 1Y18.94%
Return 3Y-33.84%
Return 5Y—

Ownership

Insiders Held0.00%
Institutions Held0.02%
Institutions Float Held0.02%
Institutional HolderSharesReport Date
ADVISORS' INNER CIRCLE III-Penn Mutual AM 1847 Income Fund58,0002025-09-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CHIZFChina Traditional Chinese Medicine Holdings Co. Limited $0.16 +0.00% -19.84 $821.34M 6.25%
CMOPFCosmo Pharmaceuticals N.V. $77.13 +2.66% -298.59 $1.32B 3.19%
EVOTFEvotec SE $6.69 +0.00% -3.18 $1.19B 0.00%
GNMLFGenomma Lab Internacional, S.A.B. de C.V. $0.86 +0.00% 8.85 $840.87M 5.81%
GTBIFGreen Thumb Industries Inc. $7.11 -0.70% 13.77 $1.65B 0.00%

About Nippon Shinyaku Co., Ltd.

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

Nippon Shinyaku Co., Ltd. is headquartered in JP.

Nippon Shinyaku Co., Ltd. (NPPNY) stock trades at $6.00 with a market capitalization of $1.62B. The stock is valued at a price-to-earnings (P/E) ratio of 9.11, price-to-book of 0.93, price-to-sales of 1.59. Over the past 52 weeks the stock has ranged between $5.03 and $15.21, and currently trades 60.6% below its 52-week high. It pays a dividend yielding 1.83%.

On profitability, Nippon Shinyaku Co., Ltd. generates a return on equity (ROE) of 10.94%, return on capital employed of 10.86%, an operating margin of 19.34%, a net profit margin of 17.40%.

Official website: www.nippon-shinyaku.co.jp

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides